Comparative Pharmacology
Head-to-head clinical analysis: MESTINON versus REVERSOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MESTINON versus REVERSOL.
MESTINON vs REVERSOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits acetylcholinesterase, preventing breakdown of acetylcholine and increasing its concentration at cholinergic synapses, thereby enhancing neuromuscular transmission.
Reversal agent for neuromuscular blockade; inhibits acetylcholinesterase, increasing acetylcholine concentration at nicotinic receptors to reverse nondepolarizing neuromuscular blocking agents.
Myasthenia gravis: 60-150 mg orally every 3-4 hours, up to 1.2 g/day. Extended-release: 180-540 mg orally once or twice daily.
0.25-0.5 mg/kg IV bolus over 10 seconds, repeated if necessary up to a maximum total dose of 2 mg/kg.
None Documented
None Documented
The terminal elimination half-life is approximately 1.5 to 2 hours in adults. In patients with renal impairment, half-life may be prolonged (up to 6-10 hours in severe impairment), necessitating dose adjustment.
Terminal elimination half-life is 8-12 hours in healthy adults (mean 10 hours). In hepatic impairment, increases up to 18 hours; in severe renal impairment (CrCl <30 mL/min), half-life may extend to 24 hours.
Renal excretion of unchanged drug and metabolites accounts for approximately 80-90% of elimination, with a small fraction (10-20%) eliminated in feces via biliary secretion.
Primarily renal excretion of unchanged drug (60-70%). Fecal elimination accounts for 20-25% via biliary secretion. Minor metabolism (<10%) with metabolites also renally cleared.
Category C
Category C
Cholinesterase Inhibitor
Cholinesterase Inhibitor